Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption in GBM Patients
InSightec
InSightec
Achieve Life Sciences
Bristol-Myers Squibb
Arvinas Inc.
Hangzhou Hanx Biopharmaceuticals, Ltd.
Merck Sharp & Dohme LLC
ImmunityBio, Inc.
Pfizer
AstraZeneca
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Bristol-Myers Squibb
Karyopharm Therapeutics Inc
BeOne Medicines
Hoffmann-La Roche
NaviFUS Corporation
Takeda
Alume Biosciences, Inc.
Travera Inc
Janssen-Cilag Ltd.
Novartis
Gilead Sciences
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Takeda
NaviFUS Corporation
Hoffmann-La Roche
Pfizer
Sandoz
Fresenius Kabi Taiwan Ltd.
Novartis
Otsuka Pharmaceutical Co., Ltd.
AbbVie
Chipscreen Biosciences, Ltd.
Takeda
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
IO Biotech
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
AstraZeneca
Novartis
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Novartis
Erbe Elektromedizin GmbH
Amgen
Bristol-Myers Squibb
AstraZeneca
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Koelis
Tasly Pharmaceutical Group Co., Ltd
Lumos Pharma
Hoffmann-La Roche